Pain Management

Mylan Inc. has introduced 3 generic versions of existing drugs to the US market, including the first and only available intermediate dosages of transdermal fentanyl.

More than 300 pharmacy students, technicians, and pharmacists helped raise nearly $6500 at the 2015 Mid-Year Conference of the Pennsylvania Pharmacists Association.

I distinctly remember feeling surprised when the FDA approved the first single entity and extended-release hydrocodone pain medication.

Are pharmacists fully aware of the warnings associated with the medications they dispense?

Most people hear "hospice" and think "cancer," but many end-stage chronic obstructive pulmonary disease patients also receive hospice care when their caregivers can no longer provide the medical attention they need.

Dispensing higher opioid doses to chronic pain patients could trigger depression.

Narcotics are not recommended for managing chronic pain in children with inflammatory bowel disease, due to gastrointestinal side effects and potential dependence. Nevertheless, researchers have uncovered that long-term narcotic use is more than twice as prevalent in pediatric IBD patients compared with the general population.

Hospira is voluntarily recalling 63 lots of its ketorolac tromethamine injection following a confirmed report of calcium-ketorolac crystals floating in glass vials of the product.

The FDA has accepted for review a New Drug Application for Inspirion Delivery Technologies' investigational opioid analgesic, MorphaBond ER, an abuse-deterrent formulation of extended-release morphine.

A primary goal of managing atrial fibrillation is relief of symptoms that include dizziness, fatigue, palpitations, shortness of breath, and chest pain. Yet, it is symptomless in up to one-third of patients.

Drug addiction is one thing, but diverting that poison onto the streets when pharmacists are told in no uncertain terms not to do so isn't looked upon so forgivingly.

While extended-release opioid analgesics are an essential component of pain management, abuse and misuse of these medications can cause substantial morbidity and mortality.

Not every patient requires an aspirin a day.

The rate of deaths from opiate medications in the United States has increased 4-fold over the past decade.

Food and Drug Administration (FDA) recently approved (PDF) DylojectTM Injection, a proprietary nonsteroidal anti-inflammatory drug meant for adults to manage mild to moderate pain and moderate to severe pain alone or in combination with opioid analgesics.

Community pharmacists can identify and educate patients at high risk for acute kidney injury related to use of nonsteroidal anti-inflammatory drugs.

With Americans' use of opioids increasing, a panel from the National Institutes of Health set out to measure the drugs' effectiveness in treating long-term chronic pain, and its report suggested that the risks outweigh the benefits.

It is not inconceivable that a physician who denies requests for opiates may not receive favorable ratings, which may impact their hospital privileges.

Two elderly health care professionals in Houston were recently charged with peddling 1.6 million pain medications over a 3-year period.

Can women who are pregnant be treated safely for acute or chronic severe pain without affecting the unborn child?

The FDA today approved Hospira Inc's diclofenac sodium injection, a proprietary nonsteroidal anti-inflammatory drug analgesic, for the treatment of mild to moderate pain or for the management of moderate to severe pain alone or in combination with opioid analgesics among adults.

John W. Devlin, PharmD, FCCM, FCCP, a clinical pharmacist in the medical ICU at Tufts Medical Center, discusses key considerations for treating delirium in the ICU.

John W. Devlin, PharmD, FCCM, FCCP, a clinical pharmacist in the medical ICU at Tufts Medical Center, discusses what he's learned from using sedation for pain and delirium in critically ill patients.

John W. Devlin, PharmD, FCCM, FCCP, a clinical pharmacist in the medical ICU at Tufts Medical Center, discusses current practice guidelines for pain and delirium that would be important for pharmacists.

Mylan Inc. announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex® Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.